die('
Site is under construction
Dear site users
Site is under construction.
The site will be ready in less than 24 hours.
We are sorry for the inconvenience.
www.yektaweb.com
');
Reports of Biochemistry and Molecular Biology
rbmb.net
Basic Sciences
http://rbmb.net
1
admin
2322-3480
2322-3480
10.61882/rbmb
en
jalali
1400
5
1
gregorian
2021
8
1
10
2
online
1
fulltext
en
Signaling Pathway in the Osmotic Resistance Induced by Angiotensin II AT2 Receptor Activation in Human Erythrocytes
زیست شناسی سلولی
Cell Biology
مقالات اصلی
Original Article
<div style="text-align: justify;"><strong><em>Background:</em></strong> Angiotensin II regulates blood volume via AT1 (AT1R) and AT2 (AT2R) receptors. As cell integrity is an important feature of mature erythrocyte, we sought to evaluate,<em> in vitro</em>, whether Angiotensin II modulates resistance to hemolysis and the signaling pathway involved.<br>
<br>
<strong><em>Methods: </em></strong>Human blood samples were collected and hemolysis assay and angiotensin II signaling pathway profiling in erythrocytes were done.<br>
<br>
<strong><em>Results:</em></strong> Hemolysis assay created a hemolysis curve in presence of Ang II in several concentrations (10<sup>-6 </sup>M, 10<sup>-8 </sup>M, 10<sup>-10 </sup>M, 10<sup>-12 </sup>M). Angiotensin II demonstrated protective effect, both in osmotic stressed and physiological situations, by reducing hemolysis in NaCl 0.4% and 0.9%. By adding receptors antagonists (losartan, AT1R antagonist and PD 123319, AT2R antagonist) and/or signaling modulators for AMPK, Akt/PI3K, p38 and PKC we showed the protective effect was enhanced with losartan and abolished with PD 123319. Also, we showed activation of PKC as well as PI3K/Akt pathways in this system.<br>
<br>
<strong><em>Conclusions:</em></strong> Briefly, Ang II protects human erythrocytes from hypo-osmotic conditions-induced hemolysis by activating AT2 receptors and triggering both the intracellular pathways.</div>
Angiotensin II, Erythrocyte, Osmotic fragility, Signaling pathway.
314
326
http://rbmb.net/browse.php?a_code=A-10-713-1&slc_lang=en&sid=1
Camila Cristina
Guimarães-Nobre
100319475328460012682
100319475328460012682
No
Grupo de Pesquisa em Fisiologia Eritróide - GPFisEri, Universidade Federal do Rio de Janeiro, Campus Macaé, Brazil & Programa de Pós-graduação em Endocrinologia, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Brazil.
Evelyn
Mendonça-Reis
100319475328460012683
100319475328460012683
No
Grupo de Pesquisa em Fisiologia Eritróide - GPFisEri, Universidade Federal do Rio de Janeiro, Campus Macaé, Brazil & Programa de Pós-graduação em Endocrinologia, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Brazil.
Luana
Passinho-da-Costa
100319475328460012684
100319475328460012684
No
Grupo de Pesquisa em Fisiologia Eritróide - GPFisEri, Universidade Federal do Rio de Janeiro, Campus Macaé, Brazil & Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Campus Macaé, Brazil.
Leandro
Miranda-Alves
100319475328460012685
100319475328460012685
No
Laboratório de Endocrinologia Experimental- LEEx, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil & Programa de Pós-graduação em Endocrinologia, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Brazil & Programa de Pós-graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil.
Clemilson
Berto-Junior
100319475328460012686
100319475328460012686
Yes
Grupo de Pesquisa em Fisiologia Eritróide - GPFisEri, Universidade Federal do Rio de Janeiro, Campus Macaé, Brazil & Laboratório de Endocrinologia Experimental- LEEx, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil & Programa de Pós-graduação em Endocrinologia, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Brazil & Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Campus Macaé, Brazil.